Clinical Trial Detail

NCT ID NCT02681302
Title Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence (CPIT001)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Hackensack Meridian Health
Indications

multiple myeloma

lymphoma

diffuse large B-cell lymphoma

Therapies

Ipilimumab + Nivolumab

Age Groups: adult senior

Additional content available in CKB BOOST